Literature DB >> 2403747

Comparison of acellular and whole-cell pertussis-component DTP vaccines. A multicenter double-blind study in 4- to 6-year-old children.

C M Morgan1, D A Blumberg, J D Cherry, K S Reisinger, M M Blatter, J L Blumer, C L Dekker, M G Stout, P D Christenson.   

Abstract

An acellular pertussis-component combined diphtheria and tetanus toxoids, and pertussis (APDT) vaccine adsorbed was compared with a licensed whole-cell pertussis-component combined diphtheria and tetanus toxoids, and pertussis (DTP) vaccine adsorbed for reactogenicity and immunogenicity when given as the fifth DTP immunization to eighty-two 4- to 6-year-old children. The reaction rates with both vaccines were low; APDT vaccine recipients had significantly less pain and warmth at the injection site than did DTP vaccine recipients. Antibody responses to pertussis antigens (lymphocytosis-promoting factor, filamentous hemagglutinin, and agglutinogens) and to diphtheria and tetanus toxoids were all brisk. The APDT vaccine recipients had a more marked response in antibodies to filamentous hemagglutinin and a less marked response in agglutinins than whole-cell vaccine recipients. On the day after immunization, both APDT and DTP vaccine recipients had an increase in mean leukocyte and neutrophil counts. This APDT vaccine is immunogenic and less reactogenic than a DTP vaccine with a whole-cell pertussis component when administered as a booster to 4- to 6-year-old children.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2403747     DOI: 10.1001/archpedi.1990.02150250047029

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  7 in total

1.  Pertussis vaccine controversies and acellular pertussis vaccine.

Authors:  Raju C Shah; Anuj R Shah
Journal:  Indian J Pediatr       Date:  2003-06       Impact factor: 1.967

2.  Isotype and antigen specificity of pertussis agglutinins following whole-cell pertussis vaccination and infection with Bordetella pertussis.

Authors:  C M Mink; C H O'Brien; S Wassilak; A Deforest; B D Meade
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

3.  Immunogenicity and safety of a monovalent, multicomponent acellular pertussis vaccine in 15 month-6-year-old German children. Monovalent Acellular Pertussis Vaccine Study Group.

Authors:  K Stehr; U Heininger; R Uhlenbusch; P Angersbach; J Hackell; T Eckhardt
Journal:  Eur J Pediatr       Date:  1995-03       Impact factor: 3.183

Review 4.  Which strategy for pertussis vaccination today?

Authors:  Dorota Z Girard
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 5.  Acellular pertussis vaccines. Towards an improved safety profile.

Authors:  M E Pichichero
Journal:  Drug Saf       Date:  1996-11       Impact factor: 5.606

6.  Acellular pertussis diphtheria-tetanus-pertussis vaccine containing separately purified pertussis toxoid, filamentous haemagglutinin and 69 kDa outer membrane protein as a booster in children.

Authors:  G Kanra; M Ceyhan; D Vandevoorde; H Bogaerts
Journal:  Eur J Pediatr       Date:  1993-06       Impact factor: 3.183

7.  Seroprevalence of diphtheria toxoid IgG antibodies in children, adolescents and adults in Poland.

Authors:  Aleksandra A Zasada; Waldemar Rastawicki; Natalia Rokosz; Marek Jagielski
Journal:  BMC Infect Dis       Date:  2013-11-19       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.